Literature DB >> 11260383

Clinical and pathologic features of focal segmental glomerulosclerosis with mitochondrial tRNALeu(UUR) gene mutation.

O Hotta1, C N Inoue, S Miyabayashi, T Furuta, A Takeuchi, Y Taguma.   

Abstract

BACKGROUND: Several families have been described in which an A to G transition mutation at position 3243 (A3243G) of the mitochondrial DNA (mtDNA) is associated with focal and segmental glomerulosclerosis (FSGS). However, the prevalence, clinical features, and pathophysiology of FSGS carrying mtDNA mutations are largely undefined.
METHODS: Among 11 biopsy-proven primary FSGS patients of unknown etiology, we examined seven FSGS patients to determine whether any of the clinical and pathological features of FSGS were associated with an A3243G mtDNA mutation. In four subjects in whom the A3243G mtDNA mutation was discovered in blood leukocytes, as well as in urine sediments, we retrospectively reviewed the medical records and re-evaluated the renal biopsy specimen using light and electron microscopy. We further screened the patient's family members for the presence and degree of heteroplasmy for this mtDNA mutation and obtained medical histories that were consistent with mitochondrial cytopathy.
RESULTS: The four individuals identified with the A3243G mtDNA mutation were female. Proteinuria was diagnosed in these individuals during a routine annual health checkup in their teenage years. None of the patients showed any symptoms related to mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episode, whereas diabetes mellitus in two of the patients and a hearing disturbance in one patient became manifest within a 3- to 13-year follow-up period. Strict maternal transmitted inheritance was confirmed by pedigree studies in all of these patients. Steroid therapy was ineffective in all four patients. In two of these patients, renal function declined slowly to end-stage renal failure. Histologic examination of biopsy specimens revealed that glomeruli were not hypertrophied, while electron microscopic examination identified severely damaged, multinucleated podocytes containing extremely dysmorphic abnormal mitochondria in all patients.
CONCLUSIONS: FSGS may belong to the spectrum of renal involvement in A3243G mtDNA mutation in humans. Severely injured podocytic changes containing abnormal mitochondria may explain the pathogenesis of FSGS in association with the A3243G mtDNA mutation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11260383     DOI: 10.1046/j.1523-1755.2001.0590041236.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  40 in total

1.  Recurrent kidney stones in a family with a mitochondrial disorder due to the m.3243A>G mutation.

Authors:  M Bargagli; G Primiano; A Primiano; J Gervasoni; A Naticchia; S Servidei; G Gambaro; P M Ferraro
Journal:  Urolithiasis       Date:  2018-11-07       Impact factor: 3.436

2.  Bioenergetic characterization of mouse podocytes.

Authors:  Yoshifusa Abe; Toru Sakairi; Hiroshi Kajiyama; Shashi Shrivastav; Craig Beeson; Jeffrey B Kopp
Journal:  Am J Physiol Cell Physiol       Date:  2010-05-05       Impact factor: 4.249

3.  Respiratory chain deficiency presenting as congenital nephrotic syndrome.

Authors:  Alice Goldenberg; Linh Huynh Ngoc; Marie-Christine Thouret; Valérie Cormier-Daire; Marie-France Gagnadoux; Dominique Chrétien; Catherine Lefrançois; Vanna Geromel; Agnès Rötig; Pierre Rustin; Arnold Munnich; Véronique Paquis; Corinne Antignac; Marie-Claire Gubler; Patrick Niaudet; Pascale de Lonlay; Etienne Bérard
Journal:  Pediatr Nephrol       Date:  2005-01-29       Impact factor: 3.714

4.  The kd/kd mouse is a model of collapsing glomerulopathy.

Authors:  Laura Barisoni; Michael P Madaio; Maria Eraso; David L Gasser; Peter J Nelson
Journal:  J Am Soc Nephrol       Date:  2005-08-24       Impact factor: 10.121

5.  Mitochondrial encephalopathy with lactic acidosis and stroke-like episodes syndrome with hypothyroidism and focal segmental glomerulosclerosis in a paediatric patient.

Authors:  Keith K Lau; Samuel P Yang; Maha N Haddad; Lavjay Butani; Sudesh P Makker
Journal:  Int Urol Nephrol       Date:  2007-02-10       Impact factor: 2.370

Review 6.  Molecular genetic analysis of podocyte genes in focal segmental glomerulosclerosis--a review.

Authors:  M M Löwik; P J Groenen; E N Levtchenko; L A Monnens; L P van den Heuvel
Journal:  Eur J Pediatr       Date:  2009-06-27       Impact factor: 3.183

7.  Retinal and renal complications in patients with a mutation of mitochondrial DNA at position 3,243 (maternally inherited diabetes and deafness). A case-control study.

Authors:  P Massin; D Dubois-Laforgue; T Meas; M Laloi-Michelin; H Gin; B Bauduceau; C Bellanné-Chantelot; E Bertin; J-F Blickle; B Bouhanick; J Cahen-Varsaux; S Casanova; G Charpentier; P Chedin; O Dupuy; A Grimaldi; B Guerci; E Kaloustian; A Lecleire-Collet; F Lorenzini; A Murat; H Narbonne; F Olivier; V Paquis-Flucklinger; M Virally; M Vincenot; B Vialettes; J Timsit; P J Guillausseau
Journal:  Diabetologia       Date:  2008-06-26       Impact factor: 10.122

Review 8.  Transforming growth factor-β, bioenergetics, and mitochondria in renal disease.

Authors:  Gabriella Casalena; Ilse Daehn; Erwin Bottinger
Journal:  Semin Nephrol       Date:  2012-05       Impact factor: 5.299

9.  Mpv17 in mitochondria protects podocytes against mitochondrial dysfunction and apoptosis in vivo and in vitro.

Authors:  Gabriela Casalena; Stefanie Krick; Ilse Daehn; Liping Yu; Wenjun Ju; Shaolin Shi; Su-yi Tsai; Vivette D'Agati; Maja Lindenmeyer; Clemens D Cohen; Detlef Schlondorff; Erwin P Bottinger
Journal:  Am J Physiol Renal Physiol       Date:  2014-03-05

10.  A familial case of mitochondrial disease resembling Alport syndrome.

Authors:  Hayahiko Fujii; Yoshihiro Mori; Kou Kayamori; Toru Igari; Eisaku Ito; Takumi Akashi; Yoshihiro Noguchi; Ken Kitamura; Tomokazu Okado; Yoshio Terada; Eiichiro Kanda; Tatemitsu Rai; Shinichi Uchida; Sei Sasaki
Journal:  Clin Exp Nephrol       Date:  2008-01-09       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.